Stock Watch: Novartis Softens Up The Market For BMS And Sanofi
Third-Quarter Earnings Suddenly Get Worse
Executive Summary
Earnings season was not going too badly until a spate of self-inflicted wounds by BMS and Sanofi soured sentiment. Many new product launches remained too small to help.
You may also be interested in...
Sanofi Stock Slides On Lower Profit Forecast And Consumer Health Spinoff Plan
The French drugmaker is significantly upping its R&D spend and exiting consumer care, a strategy CEO Paul Hudson has stoutly defended following a slump in the share price.
Stock Watch: Positive Q3 For Johnson & Johnson Post-Kenvue
J&J’s separation from its consumer division increased its cash, reduced its share count and provided interest income greater than third-quarter worldwide sales of some of its new drugs.
Stock Watch: Where Novo And Lilly Lead, Others Follow
AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.